Answers are grounded in this paper and cite their sources.
Phase III trial evaluates infigratinib's efficacy in advanced cholangiocarcinoma, suggesting a need for improved trial frameworks.
Early termination limited the ability to draw definitive conclusions on the efficacy of infigratinib as first-line treatment of FGFR2-rearranged CCA. This study illustrates the challenges of powering confirmatory studies in biomarker-selected subpopulations of rare tumors and highlights the need for regulatory collaboration to develop pragmatic frameworks for assessing novel therapies in ultra-rare malignancies.
No takes yet. Share an insight, caveat, or question.
Abou-Alfa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: